Literature DB >> 28283925

Prevention of myopia by partial correction of hyperopia: a twins study.

Antonio Medina1,2.   

Abstract

PURPOSE: To confirm the prediction of emmetropization feedback theory that myopia can be prevented by correcting the hyperopia of a child at risk of becoming myopic.
METHODS: We conducted such myopia prevention treatment with twins at risk. Their hyperopia was partially corrected by one half at age 7 and in subsequent years until age 16.
RESULTS: Hyperopia progressively decreased in all eyes as expected. None of the twins developed myopia. The spherical equivalent refractions of the followed eyes were +1 and +1.25 D at age 16. Feedback theory accurately predicted these values.
CONCLUSIONS: The treatment of the twins with partial correction of their hyperopia was successful. Prevention of myopia with this technique is relatively simple and powerful. The use of this myopia prevention treatment has no adverse effects. This prevention treatment is indicated in children with a hyperopic reserve at risk of developing myopia.

Entities:  

Keywords:  Emmetropia; Emmetropization; Feedback; Hyperopia; Myopia; Myopia prevention

Mesh:

Substances:

Year:  2017        PMID: 28283925     DOI: 10.1007/s10792-017-0493-7

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  21 in total

1.  Bifocal control of myopia.

Authors:  K H Oakley; F A Young
Journal:  Am J Optom Physiol Opt       Date:  1975-11

2.  A retrospective study of myopia progression in adult contact lens wearers.

Authors:  Mark A Bullimore; Lisa A Jones; Melvin L Moeschberger; Karla Zadnik; Rick E Payor
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

3.  Monovision slows juvenile myopia progression unilaterally.

Authors:  J R Phillips
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

4.  Prediction of Juvenile-Onset Myopia.

Authors:  Karla Zadnik; Loraine T Sinnott; Susan A Cotter; Lisa A Jones-Jordan; Robert N Kleinstein; Ruth E Manny; J Daniel Twelker; Donald O Mutti
Journal:  JAMA Ophthalmol       Date:  2015-06       Impact factor: 7.389

Review 5.  To emmetropize or not to emmetropize? The question for hyperopic development.

Authors:  Donald O Mutti
Journal:  Optom Vis Sci       Date:  2007-02       Impact factor: 1.973

6.  A model for emmetropization. The effect of corrective lenses.

Authors:  A Medina
Journal:  Acta Ophthalmol (Copenh)       Date:  1987-10

7.  Emmetropization as a first-order feedback system.

Authors:  A Medina; E Fariza
Journal:  Vision Res       Date:  1993-01       Impact factor: 1.886

8.  Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).

Authors:  Audrey Chia; Wei-Han Chua; Yin-Bun Cheung; Wan-Ling Wong; Anushia Lingham; Allan Fong; Donald Tan
Journal:  Ophthalmology       Date:  2011-10-02       Impact factor: 12.079

9.  The progression of corrected myopia.

Authors:  Antonio Medina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-12       Impact factor: 3.117

10.  Education, reading, and familial tendency as risk factors for myopia in Hong Kong fishermen.

Authors:  L Wong; D Coggon; M Cruddas; C H Hwang
Journal:  J Epidemiol Community Health       Date:  1993-02       Impact factor: 3.710

View more
  3 in total

Review 1.  The equations of ametropia: Predicting myopia.

Authors:  Francisco Gaya; Antonio Medina
Journal:  J Optom       Date:  2021-09-29

2.  Spontaneous resolution of a traumatic cataract in a patient with an open-globe ocular injury: a case report.

Authors:  Yu-Ting Zhang; Li-Qun Du; Mei Liu; Jing Zhu
Journal:  BMC Ophthalmol       Date:  2020-07-13       Impact factor: 2.209

3.  The relationship between education levels, lifestyle, and religion regarding the prevalence of myopia in Israel.

Authors:  Sharon Armarnik; Maya Lavid; Sharon Blum; Tamara Wygnanski-Jaffe; David B Granet; Michael Kinori
Journal:  BMC Ophthalmol       Date:  2021-03-16       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.